Loading...
XSTOSEZI
Market cap58mUSD
Dec 23, Last price  
5.78SEK
1D
-0.34%
1Q
-6.02%
Jan 2017
-12.73%
IPO
-2.72%
Name

Senzime AB (publ)

Chart & Performance

D1W1MN
XSTO:SEZI chart
P/E
P/S
18.32
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
15.56%
Rev. gr., 5y
61.90%
Revenues
36m
+154.77%
000298,3431,235,019541,155152,6271,628,000189,0003,214,0006,711,0009,337,00010,980,00014,034,00035,754,000
Net income
-134m
L+1.09%
-1,721,470-2,354,674-2,100,326-4,392,512-5,597,835-6,191,678-7,580,563-9,412,000-13,027,000-25,621,000-33,675,000-47,445,000-82,143,000-132,700,000-134,149,000
CFO
-114m
L-16.72%
-1,603,309-2,119,541-1,950,783-6,063,884-5,429,576-3,847,443-6,413,380-10,004,000-12,292,000-17,733,000-27,135,000-38,335,000-81,328,000-136,778,000-113,908,000
Earnings
Feb 13, 2025

Profile

Senzime AB (publ), a medical device company, develops and markets patient monitoring systems to monitor patients under anesthesia in Europe, Oceania, Asia, Canada, and the United States. The company offers TetraGraph, a monitor that stimulates, measures, analyzes, and displays muscle function in surgical patients receiving neuromuscular blocking agents; TetraSens electrode array, which has two proximal stimulating electrodes for recording and reference; TetraConnect, a data management portal that helps clinician to access, view, and export data records from the TetraGraph in PDF or Excel format; TetraGraph Device Connectivity, which transfers data from the TetraGraph Monitor to patient monitoring systems; and TetraGraph Philips Interface that enables the transmission of neuromuscular monitoring parameters, TOFC, TOFR, PTC, and TOF bars to Philips patient monitors, as well as TetraGraph readings are displayed on the Philips Intellivue Monitor. It also develops CliniSenz Analyzer for postoperative and continuous patient monitoring in hospital environments; and Onzurf Probe, a sterile CE-marked single use product based on micro-dialysis technology that enables continuous sampling from gastro-intestinal organs, such as esophagus, stomach, and liver. Senzime AB (publ) has a strategic license and connectivity agreement with Masimo to develop and market the TetraGraph Smart Cable Module that connects directly to Root monitoring system, as well as to their digital hubs to interface with the hospital clinical information system/electronic health records. The company was incorporated in 1999 and is based in Uppsala, Sweden.
IPO date
Jun 18, 2008
Employees
45
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
35,754
154.77%
14,034
27.81%
10,980
17.60%
Cost of revenue
169,567
152,277
96,138
Unusual Expense (Income)
NOPBT
(133,813)
(138,243)
(85,158)
NOPBT Margin
Operating Taxes
(3,010)
(1,658)
(2,146)
Tax Rate
NOPAT
(130,803)
(136,585)
(83,012)
Net income
(134,149)
1.09%
(132,700)
61.55%
(82,143)
73.13%
Dividends
Dividend yield
Proceeds from repurchase of equity
265,199
94,744
BB yield
-38.68%
-13.06%
Debt
Debt current
2,890
2,537
1,017
Long-term debt
20,046
23,549
2,251
Deferred revenue
Other long-term liabilities
3,750
2,886
1,735
Net debt
(128,073)
51
(71,604)
Cash flow
Cash from operating activities
(113,908)
(136,778)
(81,328)
CAPEX
(950)
(5,108)
(2,974)
Cash from investing activities
(7,821)
(4,977)
(2,974)
Cash from financing activities
246,511
92,364
(945)
FCF
(145,888)
(153,435)
(92,785)
Balance
Cash
151,009
26,035
74,872
Long term investments
Excess cash
149,221
25,333
74,323
Stockholders' equity
(506,190)
(374,826)
(246,973)
Invested Capital
896,885
651,717
399,506
ROIC
ROCE
EV
Common stock shares outstanding
92,269
67,554
63,362
Price
7.43
-30.82%
10.74
-52.89%
22.80
-5.00%
Market cap
685,562
-5.51%
725,526
-49.78%
1,444,658
5.64%
EV
557,489
725,577
1,373,054
EBITDA
(116,275)
(122,693)
(74,171)
EV/EBITDA
Interest
798
430
79
Interest/NOPBT